Tirzepatide in HFpEF With Obesity: Results From the SUMMIT Trial
ABSTRACT:
Study at a glance
- Publication type: International, double-blind, randomized, placebo-controlled trial
- What it examined: SUMMIT enrolled 731 people with HFpEF and obesity to compare tirzepatide with placebo for at least 52 weeks.
- Key point: The composite of cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo (HR 0.62; 95% CI 0.41-0.95). Gastrointestinal adverse events leading to discontinuation occurred in 6.3% and 1.4%, respectively.
Why it matters
The trial addresses a defined population—HFpEF with obesity. Its findings do not establish that the treatment is appropriate for every person with heart failure.
Source
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024. PMID: 39555826. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.
